In addition, individuals resilient to develop MDD in spite of a familial predisposition have lower striatal 5‐HT4R binding (Madsen et al., 2014) and preclinical evidence suggests that the 5HT4R is a potential target for fast‐acting antidepressant treatment (Vidal et al., 2014). Here, HTR4 is linked to major depressive disorder.